Why the Invion share price rocketed 225% higher today

The Invion Ltd (ASX:IVX) share price is rocketing higher on Wednesday. Here's why…

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the best performers on the Australian share market on Wednesday has been the Invion Ltd (ASX: IVX) share price.

The clinical-stage drug development company's shares rocketed an incredible 225% higher at one stage today. They have since given back a good portion of these gains but are still up 125% at the time of writing.

Why is the Invion share price rocketing higher?

Investors have been fighting to get hold of the company's shares on Wednesday following the release of results from a pre-clinical study undertaken by Hudson Institute of Medical Research.

This study relates to the first batch of its Australian-made Photosoft compound on mice with ovarian cancer.

Photosoft technology is an improved next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and visible light in combination with oxygen to produce cytotoxic-reactive oxygen that kills malignant cells, shuts down tumours, and stimulates the immune system.

It is a potential alternative to surgery and, in contrast to radiotherapy and chemotherapy which are mostly immunosuppressive, PDT causes acute inflammation, expression of heat-shock proteins, and invasion and infiltration of a tumour by leukocytes.

The results.

According to today's update, researchers at Hudson Institute analysed both immediate and medium-term effects on tumours and made positive observations.

This includes Photosoft causing the immediate and specific death of tumour tissue, with no apparent adverse effects in the surrounding healthy tissues. Furthermore, researchers found the size of the tumours in animals treated with Photosoft reduced to less than half of their original size over a three-week period.

Another important finding was that researchers observed that tumour destruction was accompanied by an influx of immune cells. This indicates an anti-tumour immune response. This is important because current cancer treatments can kill healthy cells and suppress the body's natural ability to fight infections.

Dr Andrew Stephens, head of the Ovarian Cancer Research at Hudson Institute, spoke very positively about the results.

He said: "These results suggest that Photosoft Technology may be an effective method to achieve targeted tumour destruction. Over the coming months we will be working with the Photosoft Technology to characterise how tumour destruction and immune response are linked, paving the way for clinical trials using Photosoft Technology as a cancer therapy."

Given how badly new treatment options are needed, I can't say I'm surprised that investors are getting excited over the results. But it is worth remembering that there is still a lot of work to be done before Photosoft potentially gets to that stage. 

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

Silhouettes of nine people climbing a steep mountain to the top at sunset, and helping each other along the way.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a pleasant Tuesday session for ASX investors today.

Read more »

Excited group of friends sitting on sofa watching sports on TV and celebrating.
Share Gainers

Why Boss Energy, Neuren, Strickland, and Vulcan shares are pushing higher today

These shares are having a better day than most today. But why?

Read more »

Woman holding gold bar and cheering.
Gold

Up 200% in 2025, guess which ASX gold stock is surging 11% again today

Investors are sending the ASX gold stock soaring again today. But why?

Read more »

Man with backpack spreading his arms out and soaking in the sun.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a volatile start to the week for the ASX share market...

Read more »

Rising share price chart.
Share Gainers

Why Canyon Resources, Nufarm, Paladin Energy, and WiseTech shares are charging higher today

These shares are starting the week on a positive note. But why?

Read more »

Man with rocket wings which have flames coming out of them.
Gold

Guess which ASX gold stock just rocketed 167% on big news!

Investors are sending the ASX gold stock flying higher on Monday. Let’s find out why.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX shares finished the trading week on a high this Friday.

Read more »